Conference item icon

Conference item

CHARIOT: Our first dose escalation trial using the time to event continual reassessment method – design, difficulties, delivery

Abstract:

CHARIOT is a single-arm open-label, phase I dose escalation trial and is the first trial examining the combination of radiotherapy, chemotherapy, and the ataxia telangiectasia mutated Rad3-related (ATR) inhibitor M6620 in patients with oesophageal cancer. The aim is to identify the maximum tolerated schedule associated with no more than a predefined target toxicity level (TTL). CHARIOT consists of three stages, each with a different TTL. CHARIOT is the first trial in our grant-funded clinical...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Role:
Author
ORCID:
0000-0002-5978-292X
More from this funder
Name:
Cancer Research UK
Grant:
20874
Publisher:
University of Cambridge
Host title:
BAYES 2018: Bayesian Biostatistics Workshop, Satellite of ISBA 2018
Journal:
BAYES 2018: Bayesian Biostatistics Workshop, Satellite of ISBA 2018 More from this journal
Publication date:
2018-06-21
Keywords:
Pubs id:
pubs:858463
UUID:
uuid:d0c50da1-0096-4d14-9da9-3724c46ea6ec
Local pid:
pubs:858463
Source identifiers:
858463
Deposit date:
2018-06-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP